Pfizer and BioAlta are looking to push the envelope on targeted antibodies, signing an agreement that gives both companies access to the other's technology.
The companies announced Dec. 7 that they will team up to develop and commercialize BioAlta's conditionally active biologic (CAB) antibody...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

